dc.creator | Falantes, José F. | es |
dc.creator | García Delgado, Regina | es |
dc.creator | Calderón Cabrera, Cristina | es |
dc.creator | Márquez Malaver, Francisco J. | es |
dc.creator | Valcárcel, D. | es |
dc.creator | De Miguel, Dunia | es |
dc.creator | Bailén, Alicia | es |
dc.creator | Bargay, Joan | es |
dc.creator | Bernal, Teresa | es |
dc.creator | González Porras, José R. | es |
dc.creator | Tormo, Mar | es |
dc.creator | Ramos, Fernando | es |
dc.creator | Andreu, Rafael | es |
dc.creator | Xicoy, Blanca | es |
dc.creator | Nomdedeu, Benet | es |
dc.creator | Brunet, Salut | es |
dc.creator | Sánchez, Joaquín | es |
dc.creator | Fernández Jurado, Antonio | es |
dc.creator | Bonabad, Santiago | es |
dc.creator | Pérez Simón, José Antonio | es |
dc.creator | Sanz, Guillermo | es |
dc.date.accessioned | 2022-02-11T07:36:33Z | |
dc.date.available | 2022-02-11T07:36:33Z | |
dc.date.issued | 2015 | |
dc.identifier.citation | Falantes, J.F., García Delgado, R., Calderón Cabrera, C., Márquez Malaver, F.J., Valcárcel, D., De Miguel, D.,...,Sanz, G. (2015). Multivariable time-dependent analysis of the impact of azacitidine in patients with lower-risk myelodysplastic syndrome and unfavorable specific lower-risk score. Leukemia Research, 39 (1), 52-57. | |
dc.identifier.issn | 0145-2126 | es |
dc.identifier.uri | https://hdl.handle.net/11441/129872 | |
dc.description.abstract | Scoring systems for lower-risk myelodysplastic syndrome (LR-MDS) recognize patients with a poorer than expected outcome. This study retrospectively analyzes the role of azacitidine in LR-MDS with adverse risk score and compared to an historical cohort treated with best supportive care or erythropoiesis-stimulating agents. Overall response to AZA was 40%. One and 2-year probabilities of survival were 62% and 45% for AZA vs. 25% and 11% (P=10(-4)). In a multivariable time-dependent analysis, response to AZA (CR/PR/HI) was associated with an improved survival (HR=0.234, 95% CI, 0.063-0.0863; P=0.029). Thrombocytopenia (<50 × 10(9)L(-1)) is confirmed as an adverse parameter in LR-MDS (HR=1.649, 95% CI, 1.012-2.687; P=0.045). | es |
dc.format | application/pdf | es |
dc.format.extent | 6 | es |
dc.language.iso | eng | es |
dc.publisher | Elsevier | es |
dc.relation.ispartof | Leukemia Research, 39 (1), 52-57. | |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.subject | Lower-risk myelodysplastic syndrome | es |
dc.subject | Outcome | es |
dc.subject | Azacitidine | es |
dc.title | Multivariable time-dependent analysis of the impact of azacitidine in patients with lower-risk myelodysplastic syndrome and unfavorable specific lower-risk score | es |
dc.type | info:eu-repo/semantics/article | es |
dcterms.identifier | https://ror.org/03yxnpp24 | |
dc.type.version | info:eu-repo/semantics/publishedVersion | es |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | es |
dc.contributor.affiliation | Universidad de Sevilla. Departamento de Medicina | es |
dc.identifier.doi | 10.1016/j.leukres.2014.10.004 | es |
dc.journaltitle | Leukemia Research | es |
dc.publication.volumen | 39 | es |
dc.publication.issue | 1 | es |
dc.publication.initialPage | 52 | es |
dc.publication.endPage | 57 | es |